CN Patent

CN105126105A — 不适合二甲双胍治疗的患者的糖尿病的治疗

Assigned to Boehringer Ingelheim International GmbH · Expires 2015-12-09 · 10y expired

What this patent protects

本发明涉及某些DPP-4抑制剂，其特别适于治疗和/或预防由于对二甲双胍不耐受或禁忌而不适合二甲双胍治疗的患者的代谢疾病，特别是糖尿病。

USPTO Abstract

本发明涉及某些DPP-4抑制剂，其特别适于治疗和/或预防由于对二甲双胍不耐受或禁忌而不适合二甲双胍治疗的患者的代谢疾病，特别是糖尿病。

Drugs covered by this patent

Patent Metadata

Patent number
CN105126105A
Jurisdiction
CN
Classification
—
Expires
2015-12-09
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.